Scinai Immunotherapeutics (SCNI) - Earnings growth in current year

Scinai Immunotherapeutics (SCNI) minimizes risks through its own GMP production while engaging external partners for clinical operations. The business relies on CDMO services and the development of anti-infective drugs, maintaining its authority in Israel through nanobodies. The 12-month earnings per share growth rate demonstrates yield dynamics, where 0.00 captures the current indicator value, helping investors filter out market noise.
Financial and market metric breakdowns for Scinai Immunotherapeutics Ltd (SCNI)

Scinai Immunotherapeutics combines the development of nanobodies for inflammation therapy with the provision of specialized IT services in the laboratory sector. This metric captures the annual trend of net income per share, reflecting the real efficiency of asset monetization relative to the previous period. Analyzing the annual EPS change ratio allows for an assessment of the business model's resilience and the impact of pipeline diversification on the issuer's financial stability.